Nicotine is an addictive alkaloid in cigarette smoke and is responsible for tobacco dependence. It is important to consider the bloodto-liver transport of nicotine to understand the nicotine elimination from the body because most of the nicotine is converted to inactive metabolites by cytochrome P450 localized in the endoplasmic reticulum of the hepatocytes. In this study, the blood-to-liver transport of nicotine was investigated by means of an in vivo portal vein injection technique in rats, and the in vitro uptake by freshly isolated rat hepatocytes was used to clarify its mechanism. The results obtained showed that the in vivo blood-to-liver transport of [ 3 H]nicotine was significantly inhibited by 50 mM nicotine and pyrilamine, suggesting involvement of a carrier-mediated transport process in the blood-toliver transport of nicotine. The in vitro uptake study using freshly isolated rat hepatocytes showed a time-and concentration-dependent uptake of [ 3 H]nicotine with a K m value of 141 mM, and the uptake was increased under alkaline extracellular conditions. In addition, intracellular acidification caused an increase in [ 3 H]nicotine uptake, suggesting that the influx transport of nicotine is driven by an oppositely directed H + gradient in hepatocytes. Moreover, [ 3 H]nicotine uptake was strongly inhibited in the presence of cationic drugs, such as pyrilamine, whereas only weak inhibitory effects were shown by substrates of typical organic cation transporters, such as tetraethylammonium, 1-methyl-4-phenylpyridinium, choline, and L-carnitine. In conclusion, a carrier-mediated system controlling the blood-to-liver transport of nicotine appears to be present on the sinusoidal membrane of hepatocytes. The pattern of inhibition and ion dependence is suggestive of an H + /organic cation antiportermediated nicotine transport system.
Introduction
Smoking is an important risk factor in diseases such as cancer, cardiovascular disease, and chronic obstructive pulmonary disease. Nearly 6 million people die from smoking-related disease each year, and this number is expected to increase to more than 8 million by 2030 (Syed and Chaudhari, 2013) , showing the great importance of smoking cessation to prevent increasingly severe health problems. Nicotine is a major alkaloid synthesized in Nicotiana tabacum and is responsible for tobacco dependence. In the brain, nicotine stimulates dopamine release from the neurons via nicotinic acetylcholine receptors and causes feelings of pleasure and reward (Dani and De Biasi, 2001 ). In addition, nicotine causes withdrawal symptoms, such as irritability and anxiety, as consequence of a reduction in its concentration in the circulating blood (Hughes et al., 1984) . Because of these neural events associated with nicotine, smokers inhale cigarette smoke repeatedly to maintain the nicotine concentration in their circulating blood, suggesting that obtaining information about the modulation of the nicotine concentration in the circulating blood will help improve the effectiveness of smoking cessation therapy.
Recently, our investigations revealed the involvement of a carriermediated transport process in the blood-to-brain transport of nicotine across the blood-brain barrier (BBB), based on the results obtained from in vivo and in vitro studies (Tega et al., 2013) . In addition, carriermediated nicotine transport has also been reported in previous studies in Caco-2 cells and rat kidney (Fukada et al., 2002a,b) , suggesting the important contribution of carrier-mediated transport to the tissue uptake of nicotine.
In the liver, it has been reported that 70-80% nicotine in the circulating blood is metabolized to cotinine by cytochrome P450 (P450) (Benowitz and Jacob, 1994) , showing that hepatic clearance plays an important role in nicotine elimination from the circulating blood. In humans, the genetic polymorphisms of CYP2A6, the hepatic enzyme involved in nicotine metabolism (Nakajima et al., 2000) , alter pharmacokinetics of nicotine, and individuals with a higher activity of CYP2A6 tend to develop tobacco dependence (Ray et al., 2009) . In an in vivo study in mice lacking the P450 enzyme involved in nicotine metabolism, the pharmacokinetic parameters for nicotine, such as its half-life in blood and the area under the blood concentration-time curve, were altered to increase the sensitivity to rewarding effects of nicotine (Li et al., 2013) . These lines of evidence strongly suggest that the hepatic clearance of nicotine affects the pharmacological response to nicotine. In terms of the interaction of nicotine with P450, nicotine transport into intracellular space across the sinusoidal membrane of hepatocytes is essential for P450-mediated metabolism of nicotine, because P450 is mainly localized in the endoplasmic reticulum of hepatocytes.
Therefore, clarification of the mechanism underlying nicotine uptake at the sinusoidal membrane of hepatocytes will provide helpful information about controlling the nicotine concentration in the circulating blood. In the present study, to examine the properties of the influx transport of nicotine by the liver, the nicotine transport was characterized using an in vivo portal vein injection technique called the liver uptake index method and freshly isolated rat hepatocytes. Liver Uptake Index Method and Cellular Uptake Study. The liver uptake index method and a cellular uptake study involving freshly isolated hepatocytes were used to investigate the in vivo and in vitro transport of nicotine in the liver, respectively. The details are described in the Supplemental Data.
Statistical Analysis. The kinetic parameters are presented as the means 6 S.D. Other data are presented as the means 6 S.E.M. To determine the significance of differences between two group means, an unpaired Student's t test was used. To assess the statistical significance of differences among means of more than two groups, one-way analysis of variance followed by Dunnett's test was used.
Results and Discussion
The in vivo hepatic uptake of [ 3 H]nicotine was 1.5-fold greater than that of [ 14 C]n-butanol, an internal reference. In the liver uptake index technique, the concentration of drugs in the space of Disse was assumed to be lower than that of the injectate by in part of mixing effect (Tsuji et al., 1990) , and the inhibitors of high concentration (50 mM) were used. As a result, unlabeled nicotine and pyrilamine significantly reduced in vivo nicotine uptake in the liver, whereas tetraethylammonium and L-carnitine had little effect (Table 1 ). These results suggest that a pyrilamine-sensitive influx system is involved in blood-to-liver transport of nicotine.
In the in vitro analysis, [
3 H]nicotine uptake exhibited time and concentration dependence, with a K m of 141 mM, a V max of 1.78 nmol/(min×mg protein) and a K d of 5.69 ml/(min×mg protein) that were estimated from the uptake data obtained at 1 minute (Fig. 1, A and B) , suggesting the involvement of a carrier-mediated transport process in nicotine uptake by rat hepatocytes. The K d was assumed to represent the nonsaturable process, including the nonspecific nicotine adsorption exhibited by the y intercept (Fig. 1A) and/or passive diffusion of nicotine. In human, nicotine concentration in the circulating blood is reported to rise to 179-370 nM after smoking (Gourlay and Benowitz, 1997) . Under the concentration range, the contribution of saturable component for total uptake clearance is estimated as 69%, suggesting the major role of carrier-mediated transport in hepatic nicotine uptake.
The study of ion-dependence suggests the extracellular Na + and membrane potential independence of hepatic nicotine uptake because of the slight and insignificant changes in [ 3 H]nicotine uptake in buffer where Na + was replaced by Li + and K + (Fig. 1C) . On the other hand, [ 3 H]nicotine uptake was reduced and increased at an extracellular pH of 6.4 and 8.4, respectively (Fig. 1D) . Intracellular acidification increased [ 3 H]nicotine uptake, and intracellular alkalization and carbonyl cyanide p-trifluoromethoxyphenylhydrazone, a protonophore, reduced the uptake (Fig. 1, E and F) , suggesting that hepatic nicotine transport is driven by an oppositely directed H + gradient. The results of the inhibition study suggest the involvement of a cation-sensitive transport system in hepatic nicotine transport, because the [ 3 H]nicotine uptake was strongly inhibited by hydrophobic cationic drugs, such as pyrilamine, verapamil, propranolol, quinidine, amantadine, and clonidine ( Table 2) . As the organic cation transporters, OCTs, OCTNs, multidrug and toxin extrusion proteins, and plasma membrane monoamine transporters are known (Gründemann et al., 1994; Tamai et al., 1997; Kekuda et al., 1998; Wu et al., 1998; Engel and Wang, 2005; Hiasa et al., 2006) ; however, the substrates or inhibitors of organic cation transporters (OCTs, OCTNs, multidrug and toxin extrusion proteins, and plasma membrane monoamine transporters) and organic anion transporters, such as tetraethylammonium, L-carnitine, 1-methyl-4-phenylpyridinium, choline, and p-aminohippurate, slightly inhibited the uptake (Table 2) , suggesting the involvement of a carrier-mediated transport process as distinct from the well-characterized transporters in hepatic nicotine transport.
Recently, the involvement of a putative pyrilamine transport system was suggested in the nicotine transport at the BBB (Okura et al., 2008; Tega et al., 2013) , and the in vitro uptake study revealed that [ 3 H]pyrilamine uptake by isolated rat hepatocytes was strongly inhibited by cationic drugs, such as nicotine, but not substrates of typical organic cation transporters (Table 2) . Although [ 3 H]pyrilamine uptake by isolated rat hepatocytes exhibited time and concentration dependence with a K m1 of 0.928 mM, a V max1 of 0.533 nmol/(min×mg protein), a K m2 of 351 mM, and a V max2 of 34.2 nmol/(min×mg protein) (Supplemental Fig. 1, A and B) , these K m values are inconsistent with the K m (28 mM) of which pyrilamine uptake by TR-BBB13 cells, an in vitro rat BBB model (Okura et al., 2008) . In addition, extracellular pH had no significant effect on [ 3 H]pyrilamine uptake by isolated rat hepatocytes (Supplemental Fig. 1C) during the pH dependence shown in pyrilamine uptake by TR-BBB13 cells (Okura et al., 2008) . These results indicate that the transport mechanism of pyrilamine in the liver is different from putative pyrilamine transport system at the BBB, suggesting that the transport mechanism, distinct from putative pyrilamine transport system at the BBB, contributes to the nicotine transport in the liver.
In a kinetic study, nicotine uptake by isolated rat hepatocytes in the presence of pyrilamine exhibited a K m of 180 mM, a V max of 0.468 nmol/(min×mg protein), and a K d of 6.03 ml/(min×mg protein) (Supplemental Fig. 2 ) that suggested the noncompetitive inhibition by pyrilamine in the liver, because the V max was significantly reduced in the presence of pyrilamine despite the closely similar K m values. In our previous report, the competitive inhibition by pyrilamine was shown in nicotine uptake by TR-BBB13 cells (Tega et al., 2013) , and these suggest that the nicotine uptake system in the liver is different from that of the BBB.
In conclusion, a carrier-mediated transport process involving the blood-to-liver transport of nicotine appears to be present on the sinusoidal membrane of the hepatocytes and is suggested to be driven by the oppositely directed H + gradient. The inhibition study suggests that a novel transporter, highly sensitive to cationic drugs, contributes to nicotine transport by the liver. These findings provide helpful information to increase our understanding of the pharmacokinetics of nicotine. 
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